Mohs / dermatologic surgery denied? We cite the Mohs AUC, NCCN, and AAD guidelines.

Why Mohs and dermatologic surgery denials are different

A denied skin-cancer surgery is rarely about cosmetics. The vast majority of Mohs cases involve biopsy-proven basal cell carcinoma, squamous cell carcinoma, or melanoma in situ on the face, ears, scalp, or hands. Yet insurers reach for the cosmetic-denial reflex anyway, especially when the procedure note includes a flap or graft that involves the nose or eyelid. Once the appeal correctly frames the surgery as oncologic extirpation with reconstructive (not cosmetic) closure, that argument falls apart.

The good news: there is a single controlling document for Mohs medical necessity — the Mohs Appropriate Use Criteria (AUC) 2012, jointly published by the American Academy of Dermatology, the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery (Connolly et al., J Am Acad Dermatol 2012;67(4):531-50). Aetna CPB 0316, UHC's Mohs medical policy, Cigna Coverage Policy 0029, and Anthem CG-SURG-25 all explicitly reference or mirror the AUC. The successful appeal quotes the AUC scenario rating Appropriate, then pairs it with NCCN BCC / SCC / Melanoma guidelines, AAD clinical guidelines, and the insurer's own policy language.

This guide walks through the most common denial categories for Mohs and dermatologic surgery, the evidence that overturns them, and the structure of an effective appeal letter.

The denial categories you will actually see

Across thousands of Mohs and dermatologic-surgery denials, six reasons account for nearly all rejections:

1. "Wide local excision would suffice" — most common; insurer claims standard excision matches Mohs cure rates.

2. "Cosmetic" — usually attached to facial reconstruction post-Mohs, occasionally to PDT for actinic keratoses.

3. "Site does not warrant Mohs" — typically used for trunk/extremity Mohs (Area L on AUC).

4. "SLNB not medically necessary" — for thin melanoma (Breslow <1mm) cases, even with high-risk features.

5. "PDT investigational" — field therapy denials, particularly for AKs.

6. "Documentation insufficient" — usually means the AUC zone, histologic subtype, or recurrence status was not clearly stated.

Each one has a specific counter, and they are not subtle.

The Mohs Appropriate Use Criteria 2012: the document that controls everything

The AUC scored 270 clinical scenarios as Appropriate, Uncertain, or Inappropriate. The framework is a four-axis matrix:

• Anatomic area: Area H (mask zone of face — central face, eyelids, eyebrows, nose, lips, chin, ear, periauricular skin, temple — plus genitalia, hands, feet, nail unit, ankles, nipples / areola), Area M (cheeks, forehead, scalp, neck, jawline, pretibial), Area L (trunk and extremities).
• Tumor histology: BCC nodular / superficial vs aggressive subtypes (infiltrative, micronodular, morpheaform, basosquamous, perineural); SCC well- vs moderately- vs poorly-differentiated; SCC with PNI; melanoma in situ / lentigo maligna; rare tumors (DFSP, microcystic adnexal carcinoma, sebaceous carcinoma, atypical fibroxanthoma, MCC).
• Size: typically <0.6cm, 0.6-1.0cm, 1.1-2.0cm, >2.0cm thresholds.
• Modifiers: primary vs recurrent, immunocompetent vs immunocompromised, healthy vs prior radiation site, well-defined vs ill-defined borders.

A successful appeal cites the patient's exact combination — for example, Area H (nasal ala) + infiltrative BCC + 1.4cm + immunocompetent + primary, which is rated Appropriate. The appeal should reference Connolly JAAD 2012 by citation, paste the four-axis description, and quote the rating.

"Wide local excision would suffice": the cure-rate counter

The reflex denial is that standard excision with 4mm margins matches Mohs. This is wrong on Area H, on aggressive histology, on recurrent tumors, and on immunocompromised patients. Mohs cure rates for primary BCC approach 99% at five years and primary SCC approach 97% — meaningfully superior to standard excision (~90% for BCC, ~92% for SCC) per the classic Rowe et al. series and confirmed in modern cohorts. The mechanism is straightforward: Mohs provides 100% peripheral and deep margin assessment of the entire excised specimen via en-face frozen sections, while standard breadloaf processing samples only a fraction of the margin.

The successful "wide local excision" counter:

• Quote the AUC scenario rating Appropriate.
• Cite Mohs cure-rate data (Rowe + modern series).
• Submit biopsy report with histologic subtype, PNI, and depth.
• For Area H lesions, emphasize tissue conservation as an independent argument — Mohs allows the smallest possible defect, which on the eyelid, nasal ala, and lip is the difference between primary closure and a complex reconstruction.
• For recurrent tumors, point out that recurrence after standard excision is itself an AUC high-risk feature making Mohs Appropriate.

"Cosmetic" denial of post-Mohs reconstruction: the most reversible denial

This denial almost always reverses on first appeal because it is unambiguously wrong. Reconstruction following Mohs extirpation of biopsy-proven skin cancer is reconstructive surgery — the defect was created by tumor removal, not by patient choice. CPT 14040-14302 (local flap), 15240-15261 (full-thickness skin graft), and 13100-13153 (complex linear closure) are reconstructive codes. The functional considerations on the face are real: eyelid closure (preventing exposure keratopathy), nasal valve patency (preventing functional airway obstruction), lip competence (preventing oral incontinence), and ear architecture (preventing hearing canal collapse).

The successful post-Mohs reconstruction appeal:

• State explicitly that the defect is post-tumor-extirpation, not elective.
• Submit operative photos of the defect with dimensions.
• Reference the reconstructive CPT codes (not cosmetic 15780 abrasion / 15823 blepharoplasty / etc.).
• Cite functional outcome considerations: eyelid closure / lacrimal drainage, nasal valve patency, lip competence, ear architecture.
• Cite AAD position that same-day reconstruction by the Mohs surgeon is standard of care for facial defects.

Trunk and extremity Mohs: Area L is on the AUC too

Insurers occasionally deny trunk or extremity Mohs as "Mohs is only for the face." The AUC explicitly addresses Area L (trunk and extremities). Mohs is Appropriate on Area L when:

• Aggressive histology is present (infiltrative, micronodular, morpheaform BCC; moderately or poorly differentiated SCC; SCC with PNI; basosquamous BCC).
• Recurrent tumor is present.
• Immunocompromised patient (solid organ transplant, CLL, HIV, immunosuppressive therapy).
• Prior radiation site.
• Size >2cm (thresholds vary by histology).
• Ill-defined borders clinically.

CPT 17313 (Mohs trunk/extremity stage 1) and 17314 (each additional stage) are dedicated trunk/extremity codes — their existence in the CPT set is itself acknowledgment that Mohs has trunk/extremity indications. Quoting the specific AUC scenario and submitting biopsy histology overturns this denial.

Sentinel lymph node biopsy for melanoma: the Breslow + ulceration + mitoses framework

SLNB denials usually target thin melanomas, particularly the Breslow <1mm range. The controlling framework is the AAD melanoma guideline (Swetter JAAD 2019), the NCCN Cutaneous Melanoma guideline (updated annually), and the AJCC 8th edition staging system (Gershenwald CA Cancer J Clin 2017).

SLNB is indicated for:

• Melanoma Breslow ≥0.8mm (T1b and higher).
• Melanoma <0.8mm with ulceration, high mitotic rate, lymphovascular invasion, or other adverse features (some guidelines treat ulceration as Breslow-equivalent).
• Patient candidates for adjuvant therapy if SLN-positive.

The pivotal trials:

• MSLT-I (Morton NEJM 2014) — SLNB-confirmed staging improved 10-year disease-free survival in intermediate-thickness melanoma (1.2-3.5mm).
• MSLT-II (Faries NEJM 2017) — completion lymph-node dissection after positive SLNB does not improve melanoma-specific survival vs nodal observation. SLNB remains the staging tool that guides adjuvant therapy decisions.
• DeCOG-SLT (Leiter Lancet Oncol 2016) — confirmatory of MSLT-II in European cohort.

The successful SLNB appeal cites Swetter 2019, NCCN, AJCC 8th, MSLT-I, and quotes the patient's exact Breslow + ulceration + mitotic rate against the threshold. Adjuvant therapy decisions (immunotherapy, BRAF/MEK targeted therapy) downstream of SLNB result are themselves a strong medical-necessity argument.

Melanoma in situ and lentigo maligna: when staged excision is the answer

Lentigo maligna (LM) is a melanoma in situ subtype with broad subclinical extension that frequently exceeds clinical borders. Standard 5mm-margin excision routinely leaves residual disease. Two surgical approaches are considered standard:

• Staged excision (square procedure / mapped serial excision / "slow Mohs") with permanent paraffin sections.
• Mohs with MART-1 immunohistochemistry to highlight melanocytes on frozen sections (Hou JAAD 2015; Etzkorn JAAD 2015).

Both achieve high cure rates (90-95%+) and superior tissue conservation vs standard excision. Insurer denials of staged excision or Mohs-with-MART-1 should cite Hou, Etzkorn, and the AAD melanoma guideline.

Photodynamic therapy and field therapy: AKs are precancerous, not cosmetic

PDT denials for actinic keratoses or superficial BCC almost always reach for "cosmetic" or "investigational." Both are incorrect.

PDT is FDA-approved:

• Levulan (5-aminolevulinic acid) + blue light — FDA 1999 for non-hyperkeratotic AKs of face and scalp.
• Ameluz (methyl/aminolevulinic acid hydrochloride) + red light — FDA 2016 for AKs of face and scalp.
• CPT 96573 (PDT external application by physician) and 96574 (debridement plus PDT) are the procedure-specific codes.

Topical field therapy is FDA-approved:

• 5-fluorouracil (Efudex / Carac / Fluoroplex) — FDA 1962.
• Imiquimod (Aldara, Zyclara) — FDA 2004 for AKs.
• Tirbanibulin (Klisyri) — FDA December 2020 for AKs of face and scalp.

The AAD AK Guideline (Eisen JAAD 2021) endorses PDT, 5-FU, imiquimod, and tirbanibulin for AKs and field cancerization. AKs are precancerous; left untreated a fraction progress to invasive SCC. The ONTRAC trial (Chen NEJM 2015) showed nicotinamide 500mg BID reduced new NMSC by 23% in high-risk patients — supporting the medical (not cosmetic) framing of field treatment.

The successful PDT / field therapy appeal cites Eisen 2021, the FDA approval, the procedure code, and submits the lesion count + biopsy if indicated.

High-risk SCC: Brigham and Women's beats AJCC for prognostication

For cutaneous SCC of the head and neck, the Brigham and Women's Hospital staging system (Karia JAMA Dermatol 2014; Jambusaria-Pahlajani JCO 2013) outperforms AJCC 8th edition for prognostication. BWH stage is based on the number of high-risk features present (tumor diameter ≥2cm, poorly differentiated histology, perineural invasion of nerves ≥0.1mm, invasion beyond subcutaneous fat). BWH T2b (2-3 high-risk features) and T3 (4 features or bone invasion) carry significantly higher recurrence, nodal metastasis, and disease-specific death rates.

The successful high-risk SCC appeal cites Karia 2014 and Jambusaria-Pahlajani 2013, lists the BWH risk features present in the patient's biopsy, and reframes the denial as inappropriate for a high-risk cancer requiring Mohs and possibly adjuvant therapy. NCCN SCC guidelines explicitly recommend Mohs for high-risk lesions and consideration of adjuvant radiation for very-high-risk features.

Documentation: what the chart must contain

Most "documentation insufficient" denials reverse once the chart contains:

1. Biopsy report with histologic subtype (BCC nodular / infiltrative / micronodular / morpheaform / basosquamous; SCC well/moderately/poorly differentiated; melanoma Breslow / ulceration / mitoses), PNI, lymphovascular invasion, depth, and margin status.

2. Clinical photograph with site marked.

3. AUC scenario reference explicitly stated: "Area H (nasal ala) + infiltrative BCC + 1.4cm + immunocompetent + primary = AUC Appropriate."

4. Recurrence status if applicable, with prior treatment history.

5. Immune status documented.

6. Reconstruction plan with anticipated defect size and proposed CPT code (14040-14302 / 15240-15261 / 13100-13153) for post-Mohs cases.

The biopsy report drives almost every denial reversal. If the dermatopathologist did not specify the histologic subtype clearly, request an addendum before filing the appeal.

Medically necessary scar revision: the functional argument

Scar revision is denied as cosmetic by reflex. The successful appeal documents functional impairment:

• Eyelid ectropion with exposure keratopathy / dry eye.
• Lip incompetence with oral incontinence.
• Nasal valve collapse with airway obstruction (consider nasal endoscopy or peak nasal inspiratory flow documentation).
• Joint contracture limiting range of motion.
• Symptomatic hypertrophic / keloid scar with pruritus, pain, or recurrent ulceration.
• Distorted post-Mohs reconstruction requiring revision for functional outcome.

The American Society for Dermatologic Surgery (ASDS) guidelines distinguish medical from cosmetic scar revision. Submit photos, functional measurement (Schirmer test, visual field for eyelid, peak nasal inspiratory flow, range-of-motion measurements), and a clear functional indication.

The peer-to-peer call: demand a same-specialty Mohs surgeon

Most insurer denials carry a 14-day peer-to-peer review window. Demand it explicitly and demand a same-specialty reviewer — fellowship-trained dermatologic surgeon, ACMS Fellow, or Mohs surgeon. A general surgeon, plastic surgeon, or non-dermatologist is not a same-specialty reviewer for a Mohs case. That is a meaningful lever.

Bring three things to the call:

1. The biopsy report with subtype + PNI + margins.

2. The AUC scenario reference (Area + histology + size + recurrence + immune status).

3. The specific NCCN / AAD guideline citation that the insurer's policy mirrors.

A successful peer-to-peer often overturns the denial without a formal written appeal. Even when it doesn't, the call generates a paper trail.

Letter structure that actually works

A Mohs / dermatologic-surgery appeal letter should be 1.5 to 2 pages. Structure:

1. Header with member ID, claim #, procedure, CPT code (17311 / 17312 / 17313 / 17314 / 38500 SLNB / 96573 PDT / 14060 flap / 15260 FTSG as applicable).

2. Tumor diagnosis + ICD-10 + subsite + size + histologic subtype + recurrence + immune status (1 paragraph).

3. AUC zone determination — Area H/M/L + Appropriate / Uncertain / Inappropriate rating with the specific scenario.

4. High-risk features — aggressive histology, PNI, recurrence, prior radiation site, immunosuppression, ill-defined borders, BWH high-risk SCC stage.

5. Address the denial reason directly — quote the insurer's own coverage criteria, demonstrate each is met, cite Mohs AUC 2012 (Connolly JAAD 2012;67(4):531-50) + NCCN + AAD guideline.

6. Closing — request overturn within deadline, demand peer-to-peer with same-specialty Mohs surgeon.

Tone is professional, firm, evidence-driven. The medical director responds to citations and biopsy data, not to adjectives.

When to escalate

If the first-level appeal fails, the next step depends on plan type:

• Self-funded ERISA plans — second-level internal appeal, then external review (binding under ACA §2719).
• Fully-insured plans — state-mandated external review through the state insurance department.
• Medicare Advantage — Independent Review Entity (IRE) review, then ALJ hearing.
• Medicaid — state Fair Hearing.

Each level carries its own deadline (typically 60 to 180 days). Most denials reverse on first appeal when the AUC framework is invoked correctly and the chart already contains the right biopsy detail and clinical documentation.

What good looks like

A successful Mohs / dermatologic-surgery appeal letter:

• Quotes the insurer's own policy by name and number (Aetna CPB 0316, UHC Mohs Micrographic Surgery medical policy, Cigna Coverage Policy 0029, Anthem CG-SURG-25).
• Cites Mohs AUC 2012 (Connolly JAAD 2012;67(4):531-50) by name with the specific scenario rating.
• Cites NCCN BCC / SCC / Melanoma guidelines + AAD clinical guidelines (Kim JAAD 2018 BCC, Alam JAAD 2018 SCC, Swetter JAAD 2019 melanoma) + Eisen JAAD 2021 AK.
• Cites MSLT-I (Morton NEJM 2014) and MSLT-II (Faries NEJM 2017) for SLNB cases.
• Cites BWH staging (Karia JAMA Dermatol 2014) for high-risk SCC.
• Includes biopsy histology, PNI, margin status, and AUC scenario reference.
• Documents recurrence and immune status.
• Demands peer-to-peer with same-specialty Mohs surgeon.
• Stays within 2 pages.

Most denials reverse on first appeal when these elements are present. The work is in the documentation — once the chart contains the right biopsy detail and AUC framing, drafting the letter is mechanical.